Skip to main content
SpringerLink
Log in

WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update

  • Myeloproliferative Disorders (JJ Kiladjian, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Although the revised World Health Organization (WHO) criteria for the diagnosis and classification of myeloproliferative neoplasms (MPN) were defined by a panel of expert hematopathologists and clinicians, controversy has been repeatedly expressed questioning the clinical usefulness and reproducibility of these diagnostic guidelines. In particular, the distinction between essential thrombocythemia (ET), early/prefibrotic primary myelofibrosis (PMF) and initial stages of polycythemia vera (PV) is still a matter of debate. In this context, it has been argued that clinical correlations with histological features were not firmly substantiated. On the other hand, recently published data from independently performed studies have repeatedly validated the reproducibility of the WHO criteria and provided persuasive evidence that discrimination of early/prefibrotic PMF has a significant impact on the risk of myelofibrotic and leukemic transformation. However, as has been explicitly required, the WHO concept is based on the recognition of characteristic bone marrow patterns and a consensus of clinical and molecular data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lympoid tissues Lyon. France: IARC Press; 2008.

    Google Scholar 

  2. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.

    Article  PubMed  CAS  Google Scholar 

  3. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112:231–9.

    Article  PubMed  CAS  Google Scholar 

  4. Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009;27:2991–9.

    Article  PubMed  CAS  Google Scholar 

  5. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111:60–70.

    Article  PubMed  CAS  Google Scholar 

  6. Rüdiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;13:140–9.

    Article  PubMed  Google Scholar 

  7. Lones MA, Auperin A, Raphael M, et al. Mature B-cell lymphoma/leukemia in children and adolescents: intergroup pathologist consensus with the revised European-American Lymphoma Classification. Ann Oncol. 2000;11:47–51.

    Article  PubMed  CAS  Google Scholar 

  8. Glaser SL, Dorfman RF, Clarke CA. Expert review of the diagnosis and histologic classification of Hodgkin disease in a population-based cancer registry: interobserver reliability and impact on incidence and survival rates. Cancer. 2001;92:218–24.

    Article  PubMed  CAS  Google Scholar 

  9. • Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study of 1,104 patients. J Clin Oncol. 2011;29:3179–84. An important multicenter study that highlighted the clinical impact of WHO diagnostic criteria.

    Article  PubMed  Google Scholar 

  10. • Thiele J, Kvasnicka HM, Mullauer L, et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117:5710–8. A multicenter trial that underscored the prognostic impact of the WHO guidelines with regard to early/prefibrotic PMF.

    Article  PubMed  CAS  Google Scholar 

  11. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    Article  PubMed  CAS  Google Scholar 

  12. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22.

    Article  PubMed  CAS  Google Scholar 

  13. Kvasnicka HM, Thiele J. Classification of Ph-negative chronic myeloproliferative disorders–morphology as the yardstick of classification. Pathobiology. 2007;74:63–71.

    Article  PubMed  CAS  Google Scholar 

  14. • Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol. 2010;85:62–9. A very comprehensive review that summarized the problems of prodromal MPN.

    PubMed  Google Scholar 

  15. Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features - does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol. 2005;20:633–44.

    PubMed  CAS  Google Scholar 

  16. Thiele J, Kvasnicka HM. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features-a clinicopathological study on 272 patients. Histol Histopathol. 2003;18:93–102.

    PubMed  CAS  Google Scholar 

  17. • Barbui T, Thiele J, Vannucchi AM, et al. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013. doi:10.1038/leu.2013.74. A comprehensive survey about the current problems of the WHO criteria for the diagnosis of early stage PMF.

    Google Scholar 

  18. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders - current diagnostic approach. Semin Hematol. 2005;42:184–95.

    Article  PubMed  Google Scholar 

  19. Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk Lymphoma. 2006;47:381–96.

    Article  PubMed  Google Scholar 

  20. Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol. 2006;19:413–37.

    Article  PubMed  CAS  Google Scholar 

  21. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus for grading of bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.

    PubMed  Google Scholar 

  22. Kuter DJ, Bain B, Mufti G, et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139:351–62.

    Article  PubMed  CAS  Google Scholar 

  23. Thiele J, Kvasnicka HM. Myelofibrosis–what's in a name? Consensus on definition and EUMNET grading. Pathobiology. 2007;74:89–96.

    Article  PubMed  Google Scholar 

  24. Thiele J, Kvasnicka HM. Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol. 2005;32:380–94.

    Article  PubMed  Google Scholar 

  25. Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006;85:226–32.

    Article  PubMed  CAS  Google Scholar 

  26. Thiele J, Kvasnicka HM. Myelofibrosis in chronic myeloproliferative disorders-dynamics and clinical impact. Histol Histopathol. 2006;21:1367–78.

    PubMed  CAS  Google Scholar 

  27. • Gianelli U, Vener C, Bossi A, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol. 2012;25:1193–202. An important paper that underscores the impact of bone marrow fibrosis as prognostic marker in PMF.

    Article  PubMed  Google Scholar 

  28. Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood. 2008;111:1862–5.

    Article  PubMed  CAS  Google Scholar 

  29. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003;82:148–52.

    PubMed  CAS  Google Scholar 

  30. Brousseau M, Parot-Schinkel E, Moles MP, et al. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology. 2010;56:758–67.

    Article  PubMed  Google Scholar 

  31. Buhr T, Hebeda K, Kaloutsi V, et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97:360–5.

    Article  PubMed  Google Scholar 

  32. Florena AM, Tripodo C, Iannitto E, et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica. 2004;89:911–9.

    PubMed  Google Scholar 

  33. Kreft A, Buesche G, Ghalibafian M, et al. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol. 2005;113:137–43.

    Article  PubMed  Google Scholar 

  34. Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol. 2008;130:336–42.

    Article  PubMed  CAS  Google Scholar 

  35. Gianelli U, Vener C, Raviele PR, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma. 2006;47:1774–81.

    Article  PubMed  Google Scholar 

  36. Boiocchi L, Mathew S, Gianelli U, et al. Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. Mod Pathol. 2013.

  37. Diebold J, Anderson JR, Armitage JO, et al. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma. 2002;43:97–104.

    Article  PubMed  CAS  Google Scholar 

  38. Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93:1712–7.

    Article  PubMed  Google Scholar 

  39. Murphy S, Peterson P, Iland H, et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29–39.

    PubMed  CAS  Google Scholar 

  40. Pearson TC. Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol. 1998;11:695–720.

    Article  PubMed  CAS  Google Scholar 

  41. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol. 1999;36:9–13.

    PubMed  CAS  Google Scholar 

  42. Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010;149:352–75.

    Article  PubMed  CAS  Google Scholar 

  43. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol. 2002;70:283–91.

    Article  PubMed  Google Scholar 

  44. Thiele J, Kvasnicka HM, Schmitt-Gräff A, et al. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma. 2003;44:549–53.

    Article  Google Scholar 

  45. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45.

    Article  PubMed  CAS  Google Scholar 

  46. Thiele J, Kvasnicka HM, Vardiman JW, et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol. 2009;27:e220–1. author reply e222-223.

    Article  PubMed  Google Scholar 

  47. Thiele J, Orazi A, Kvasnicka HM, et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97(3):360–5. --comment. Haematologica 2012, 97:e5-6; discussion e7-8.

    Article  Google Scholar 

  48. • Madelung AB, Bondo H, Stamp I, et al. WHO-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations—the Danish experience. Am J Hematol. 2013. doi:10.1002/ajh.23554. In this study interobserver and intraobserver reproducibility and concordance between histological diagnosis and independently collected clinical findings in a large series of patients with the major subtypes of MPN and controls were examined.

    PubMed  Google Scholar 

  49. Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009;6:627–37.

    Article  PubMed  CAS  Google Scholar 

  50. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009.

  51. Tefferi A, Vardiman JW. The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Curr Opin Hematol. 2007;14:115–22.

    Article  PubMed  Google Scholar 

  52. Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86:1017–26.

    Article  PubMed  Google Scholar 

  53. • Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One. 2012;7:e35631. A landmark paper that supports the concept of early/prefibrotic PMF.

    Article  PubMed  CAS  Google Scholar 

  54. Kvasnicka HM, Thiele J. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol. 2004;19:1245–60.

    PubMed  CAS  Google Scholar 

  55. Thiele J, Kvasnicka HM. Prefibrotic chronic idiopathic myelofibrosis-a diagnostic enigma? Acta Haematol. 2004;111:155–9.

    Article  PubMed  CAS  Google Scholar 

  56. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452–66.

    Article  PubMed  CAS  Google Scholar 

  57. Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600 × 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol. 1998;100:15–23.

    Article  PubMed  CAS  Google Scholar 

  58. Regev A, Stark P, Blickstein D, et al. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol. 1997;56:168–72.

    Article  PubMed  CAS  Google Scholar 

  59. Sacchi S, Vinci G, Gugliotta L, et al. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC). Haematologica. 2000;85:492–5.

    PubMed  CAS  Google Scholar 

  60. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5:708–14.

    Article  PubMed  Google Scholar 

  61. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130:2031–8.

    Article  PubMed  CAS  Google Scholar 

  62. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528–34.

    Article  PubMed  CAS  Google Scholar 

  63. Smalberg JH, Murad SD, Braakman E, et al. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica. 2006;91:1712–3.

    PubMed  Google Scholar 

  64. Colaizzo D, Amitrano L, Guardascione MA, et al. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Thromb Res. 2013.

  65. Donadini MP, Dentali F, Ageno W. Splanchnic vein thrombosis: new risk factors and management. Thromb Res. 2012;129 Suppl 1:S93–6.

    Article  PubMed  CAS  Google Scholar 

  66. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111:4922–9.

    Article  PubMed  CAS  Google Scholar 

  67. Kouroupi E, Kiladjian JJ, Chomienne C, et al. The JAK2 46/1 haplotype in splanchnic vein thrombosis. Blood. 2011;117:5777–8.

    Article  PubMed  CAS  Google Scholar 

  68. Villani L, Bergamaschi G, Primignani M, et al. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. Leuk Res. 2012;36:e7–9.

    Article  PubMed  Google Scholar 

  69. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 2008;22:1308–19.

    Article  PubMed  CAS  Google Scholar 

  70. Shaw GR. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol. 2005;131:180–4.

    PubMed  Google Scholar 

  71. Ceesay MM, Lea NC, Ingram W, et al. The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia. 2006;20:2060–1.

    Article  PubMed  CAS  Google Scholar 

  72. Hyjek E, Vardiman JW. Myelodysplastic/myeloproliferative neoplasms. Semin Diagn Pathol. 2011;28:283–97.

    Article  PubMed  Google Scholar 

  73. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114:3538–45.

    Article  PubMed  CAS  Google Scholar 

  74. Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008;93:34–40.

    Article  PubMed  CAS  Google Scholar 

  75. Atallah E, Nussenzveig R, Yin CC, et al. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia. 2008;22:1295–8.

    Article  PubMed  CAS  Google Scholar 

  76. Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost. 2006;32:362–71.

    Article  PubMed  Google Scholar 

  77. Kvasnicka HM, Thiele J, Werden C, et al. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 1997;80:708–19.

    Article  PubMed  CAS  Google Scholar 

  78. Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26:716–9.

    Article  PubMed  CAS  Google Scholar 

  79. Buxhofer-Ausch V, Gisslinger B, Stangl G, et al. Successful treatment sequence incorporating bevacizumab for therapy of polyneuropathy in two patients with POEMS syndrome. Leuk Res. 2012;36:e98–100.

    Article  PubMed  Google Scholar 

  80. • Ejerblad E, Kvasnicka HM, Thiele J, et al. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. Hematology. 2013;18:8–13. The first prospective study that provided evidence about significant differences in follow-up outcome between WHO-defined ET and early/prefibrotic PMF.

    Article  PubMed  Google Scholar 

  81. • Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121:1720–8. An international prospective multicenter trial regarding WHO-defined ET and Anagrelide therapy.

    Article  PubMed  CAS  Google Scholar 

  82. • Thiele J, Kvasnicka HM. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. Semin Thromb Hemost. 2006;32:219–30. This paper highlights the problem associated with the classification of thrombocythemic MPDs.

    Article  PubMed  Google Scholar 

  83. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954–70.

    PubMed  CAS  Google Scholar 

  84. Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol. 2005;129:701–5.

    Article  PubMed  CAS  Google Scholar 

  85. Alvarez-Larran A, Ancochea A, Angona A, et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica. 2012;97:1704–7.

    Article  PubMed  Google Scholar 

  86. Cassinat B, Laguillier C, Gardin C, et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia. 2008;22:452–3.

    Article  PubMed  CAS  Google Scholar 

  87. • Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013. doi:10.1182/blood-2013-06-508416. A comprehensive study regarding the current diagnostic criteria of PV and the value of bone marrow histology.

    Google Scholar 

  88. Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2013. doi:10.1002/ajh.23585.

    Google Scholar 

  89. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117:6669–72.

    Article  PubMed  CAS  Google Scholar 

  90. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88:507–16.

    Article  PubMed  CAS  Google Scholar 

  91. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89:1194–8.

    PubMed  CAS  Google Scholar 

  92. Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol. 2005;20:317–28.

    PubMed  CAS  Google Scholar 

  93. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol. 2005;113:213–9.

    Article  PubMed  Google Scholar 

  94. Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119:2239–41.

    Article  PubMed  CAS  Google Scholar 

  95. Jantunen R, Juvonen E, Ikkala E, et al. Development of erythrocytosis in the course of essential thrombocythemia. Ann Hematol. 1999;78:219–22.

    Article  PubMed  CAS  Google Scholar 

  96. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656–64.

    Article  Google Scholar 

  97. Carobbio A, Finazzi G, Antonioli E, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009;37:1016–21.

    Article  PubMed  CAS  Google Scholar 

  98. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–70.

    Article  PubMed  Google Scholar 

  99. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Hans Michael Kvasnicka declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Senckenberg Institute of Pathology, University of Frankfurt, Theodor-Stern-Kai, 60590, Frankfurt, Germany

    Hans Michael Kvasnicka

Authors
  1. Hans Michael Kvasnicka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans Michael Kvasnicka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kvasnicka, H.M. WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update. Curr Hematol Malig Rep 8, 333–341 (2013). https://doi.org/10.1007/s11899-013-0186-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-013-0186-x

Keywords

Search

Navigation